Program
Sulfasalazine
Also written as “Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Arthritis, Juvenile · Arthritis, Rheumatoid, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 20 open or running | phase 1since Feb 11, 2020 | Feb 11, 2020 | none ahead |
| Pfizer | 20 open or running | phase 4since Jan 11, 2007 | Jan 11, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2007First study: phase 4 study in Arthritis, RheumatoidNew to PfizerPfizer · NCT00422227 · 300 enrolled · Hong Kong, India, Korea, Republic of and more
- Mar 11, 2008Phase 4 study in Arthritis, JuvenilePfizer · NCT00637780 · 2 enrolled · United States, Mexico
- Feb 11, 2020Bristol-Myers Squibb's first study: phase 1 study in Healthy VolunteerNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT04268394 · 48 enrolled · United Kingdom
- Jun 30, 2022Phase 1 study in Healthy ParticipantsBristol-Myers Squibb · NCT05445440 · 30 enrolled · United States
TargetBeta
“Arachidonate 5-lipoxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05445440Healthy Participants · United States | 1 | Completed | Bristol-Myers Squibb | Nov 17, 2022 | 30 |
| NCT04268394Healthy Volunteer · United Kingdom | 1 | Completed | Bristol-Myers Squibb | Jun 2, 2021 | 48 |
| NCT00637780Arthritis, Juvenile · United States, Mexico | 4 | Terminated | Pfizer | Jan 2014 | 2 |
| NCT00422227Arthritis, Rheumatoid · Hong Kong, India, Korea, Republic of and more | 4 | Completed | Pfizer | Mar 2009 | 300 |
How it is read
Names in the registry
- “Sulfasalazine”, 6 entries
- “Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 1 study
- Arthritis, Juvenile, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.